THE European Commission has
granted marketing authorisation in
Europe for Sanofi’s Lyxumia
(lisenatide), which is the first oncedaily
prandial GLP-1 receptor
agonist and is indicated for the
treatment of type 2 diabetes.
The approval is for Lyxumia taken
in combination with oral glucosecontaining
medicinal products and/
or basal insulin when these,
together with diet and exercise, do
not provide adequate glycaemic
control.The above article was sent to subscribers in Pharmacy Daily's issue from 05 Feb 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Feb 13
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.